InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering
anti-inflammatory therapeutics by targeting the complement system,
today announced that it will report its first quarter 2024
financial and operating results on May 8, 2024, before the market
opens. No conference call is planned for the first quarter 2024
results.
InflaRx also announced it will host a virtual
research and development event on June 5, 2024. Guided by
internationally renowned thought leaders, this event will focus on
the planned development of our new oral small molecule C5aR
inhibitor, INF904, and the role of C5aR in chronic spontaneous
urticaria (CSU) and hidradenitis suppurativa (HS). Discussions will
address underlying development rationales and expected Phase IIa
trial design and provide insights into the commercial opportunity.
In addition, we will discuss INF904's broader therapeutic potential
in the immuno-inflammation field and recent advances in our
understanding of the role of C5a/C5aR signaling as it relates to
human inflammatory diseases.
Featured key opinion leaders will include
Prof. Dr. Marcus Maurer (Professor of Dermatology
and Allergology, Institute of Allergology, Charité –
Universitätsmedizin Berlin, Germany), Christopher Sayed,
MD (Prof. of Dermatology, University of North Carolina,
Medical School; and Secretary of the HS Foundation) and
Prof. Dr. Jörg Köhl (Director of the
Institute for Systemic Inflammation Research, University of Lübeck,
Lübeck, Germany).
The R&D event will take place on June 5,
from 12:00 PM EDT / 6:00 PM CEST to 2:00 PM EDT / 8:00 PM CEST. To
participate in the virtual event, participants may pre-register
here to receive an invite link and dial-in details to access the
R&D event.
About the speakersProf.
Dr. Marcus MaurerProfessor of Dermatology and Allergology,
Institute of Allergology, Charité – Universitätsmedizin Berlin,
Germany
Dr. Maurer is a globally renowned key
opinion leader in the area of allergy and urticaria research who
has been instrumental in the global clinical development of
numerous medical therapies.
Dr. Maurer has over 25 years of experience in
the field of dermatology and allergology, with a research interest
in the biology of mast cells, in inflammation and immunology. His
clinical focus is on all areas of urticaria, allergic skin- and
mast-cell diseases. He has supervised more than 60 clinical trials,
Phase I through IV, and has contributed to more than 800
publications in peer-reviewed journals and 40 books and book
chapters. Since 2005, he has held a full Professor position at
Charité. He is a coordinator of the Global Allergy and Asthma
European Networks of urticaria and angioedema centers of reference
and excellence, UCARE and ACARE.
Dr. Maurer trained at Beth Israel Deaconess
Hospital and Harvard Medical School in Boston (1995-1998) and is
board certified for Dermatology (2000) and Allergology (2003).
Christopher Sayed, MDProfessor
of Dermatology, University of North Carolina, Medical School, and
Secretary of the HS Foundation
Dr. Sayed is an internationally
recognized global key opinion leader in the field of hidradenitis
suppurativa (HS) and has previously served as a board member of the
US HS foundation.
Dr. Sayed has over 10 years of experience in the
field of dermatology and clinical research with a special interest
in the medical and surgical management of hidradenitis suppurativa
(HS). He is the Medical Director of the HS clinic at University of
North Carolina, Chapel Hill, NC, USA. He has performed clinical and
basic science research in HS and other dermatologic conditions with
more than 65 publications in the medical literature. He serves as a
directing member of the Hidradenitis Suppurativa Foundation and is
medical lead of a local HS support group. He is board certified in
Dermatology and received his medical training at the University of
North Carolina, USA.
Prof. Dr. Jörg KöhlDirector of
the Institute for Systemic Inflammation Research, University of
Lübeck, Lübeck, Germany
Dr. Köhl is an internationally leading
translational complement scientist with a particular focus on the
role of C5a/C5aR biology and its role in human
disease.
He has over 30 years of medical and research
experience and has published over 200 papers in the complement
therapeutic landscape. His research has been continuously funded by
the National Institutes of Health, the German Research Foundation,
the Federal Ministry of Education and Research and the European
Union since 1990. He has held several senior scientific positions,
including a 20-year research appointment as Professor of Pediatrics
at Cincinnati Children’s Hospital Medical Center in the Divisions
of Molecular Immunology and Immunobiology and his current position
as the Founding Director of the Institute for Systemic Inflammation
Research at the University of Lübeck, Germany. Dr. Köhl received
his medical degree from the University of Mainz, Germany.
About InflaRx
InflaRx GmbH (Germany) and InflaRx
Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx
N.V. (together, InflaRx).
InflaRx (Nasdaq: IFRX) is a biopharmaceutical
company pioneering anti-inflammatory therapeutics by applying its
proprietary anti-C5a and anti-C5aR technologies to discover,
develop and commercialize highly potent and specific inhibitors of
the complement activation factor C5a and its receptor C5aR. C5a is
a powerful inflammatory mediator involved in the progression of a
wide variety of inflammatory diseases. InflaRx’s lead product
candidate, vilobelimab, is a novel, intravenously delivered,
first-in-class, anti-C5a monoclonal antibody that selectively binds
to free C5a and has demonstrated disease-modifying clinical
activity and tolerability in multiple clinical studies in different
indications. InflaRx is also developing INF904, an orally
administered small molecule inhibitor of C5a-induced signaling via
the C5a receptor. InflaRx was founded in 2007, and the group has
offices and subsidiaries in Jena and Munich, Germany, as well as
Ann Arbor, MI, USA. For further information, please visit
www.inflarx.de.
Contacts:
InflaRx N.V.Jan Medina, CFAVice
President, Head of Investor RelationsEmail: IR@inflarx.de
MC Services AGKatja Arnold,
Laurie Doyle, Dr. Regina LutzEmail: inflarx@mc-services.eu Europe:
+49 89-210 2280U.S.: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “estimate,” “believe,”
“predict,” “potential” or “continue,” among others. Forward-looking
statements appear in a number of places throughout this release and
may include statements regarding our intentions, beliefs,
projections, outlook, analyses and current expectations concerning,
among other things, the receptiveness of GOHIBIC (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals and
related treatment recommendations by medical/healthcare institutes
and other third-party organizations, our ability to successfully
commercialize and the receptiveness of GOHIBIC (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals or
our other product candidates; our expectations regarding the size
of the patient populations for, market opportunity for, coverage
and reimbursement for, estimated returns and return accruals for,
and clinical utility of GOHIBIC (vilobelimab) in its approved or
authorized indication or for vilobelimab and any other product
candidates, under an EUA and in the future if approved for
commercial use in the U.S. or elsewhere; our ability to
successfully implement The InflaRx Commitment Program, the success
of our future clinical trials for vilobelimab’s treatment of
COVID-19 and other debilitating or life-threatening inflammatory
indications, including PG, and any other product candidates,
including INF904, and whether such clinical results will reflect
results seen in previously conducted pre-clinical studies and
clinical trials; the timing, progress and results of pre-clinical
studies and clinical trials of our product candidates and
statements regarding the timing of initiation and completion of
studies or trials and related preparatory work, the period during
which the results of the trials will become available, the costs of
such trials and our research and development programs generally;
our interactions with regulators regarding the results of clinical
trials and potential regulatory approval pathways, including
related to our Marketing Authorization Application submission for
vilobelimab and our biologics license application submission for
GOHIBIC (vilobelimab), and our ability to obtain and maintain full
regulatory approval of vilobelimab or GOHIBIC (vilobelimab) for any
indication; whether the U.S. Food and Drug Administration, the
European Medicines Agency or any comparable foreign regulatory
authority will accept or agree with the number, design, size,
conduct or implementation of our clinical trials, including any
proposed primary or secondary endpoints for such trials; our
expectations regarding the scope of any approved indication for
vilobelimab; our ability to leverage our proprietary anti-C5a and
C5aR technologies to discover and develop therapies to treat
complement-mediated autoimmune and inflammatory diseases; our
ability to protect, maintain and enforce our intellectual property
protection for vilobelimab and any other product candidates, and
the scope of such protection; our manufacturing capabilities and
strategy, including the scalability and cost of our manufacturing
methods and processes and the optimization of our manufacturing
methods and processes, and our ability to continue to rely on our
existing third-party manufacturers and our ability to engage
additional third-party manufacturers for our planned future
clinical trials and for commercial supply of vilobelimab and for
the finished product GOHIBIC (vilobelimab); our estimates of our
expenses, ongoing losses, future revenue, capital requirements and
our needs for or ability to obtain additional financing; our
ability to defend against liability claims resulting from the
testing of our product candidates in the clinic or, if approved,
any commercial sales; if any of our product candidates obtain
regulatory approval, our ability to comply with and satisfy ongoing
obligations and continued regulatory overview; our ability to
comply with enacted and future legislation in seeking marketing
approval and commercialization; our future growth and ability to
compete, which depends on our retaining key personnel and
recruiting additional qualified personnel; and our competitive
position and the development of and projections relating to our
competitors in the development of C5a and C5aR inhibitors or our
industry; and the risks, uncertainties and other factors described
under the heading “Risk Factors” in our periodic filings with the
U.S. Securities and Exchange Commission. These statements speak
only as of the date of this press release and involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Given these risks, uncertainties and other factors, you
should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
InflaRx NV (NASDAQ:IFRX)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024